what needs to be remembered is that many of the cancer drugs are coming to the end of the patent life and will expire and then generic drugs can the ne produced.
If a new delivery system for these drugs can be show to have improved outcomes for patients like improved efficacy and less side effects than regulatory bodies like the fda can extend the life of the patent
This is where SPL in my view has a good chance of commercializing the offer or financially are worthwhile for a takeover
Ann: US patent issued for DEP cabazitaxel nanoparticle, page-15
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
